PT  - JOURNAL ARTICLE
AU  - Buckley, Rita
ED  - Gerstein, Hertzel C.
TI  - ORIGIN Trial: Insulin Glargine and n-3 Fatty Acids Neither Reduces CV Events Nor Increases Cancers in Diabetic Patients
DP  - 2012 Dec 01
TA  - MD Conference Express
PG  - 12--13
VI  - 12
IP  - 16
4099  - http://mdc.sagepub.com/content/12/16/12.short
4100  - http://mdc.sagepub.com/content/12/16/12.full
AB  - Insulin glargine used to target normal fasting glucose for more than 6 years had a neutral effect on cardiovascular (CV) outcomes and cancers in high-risk patients with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or early diabetes. Although it reduced new onset diabetes, insulin glargine also increased hypoglycemia and modestly increased weight in the Outcome Reduction with Initial Glargine Intervention Trial [ORIGIN Trial Investigators. N Engl J Med 2012]. In the same trial, daily supplementation with n-3 fatty acids did not reduce CV events.